Recently there has been a significant improvement in the treatment of HER2+ breast cancer due to HER2-targeted therapies. And yet with all the major advancements, there are no therapies approved to target p95HER2 that have been designed specifically to recruit T-cells attacking the tumor.
Taiwanese company AP Biosciences has announced that its first patient has been dosed in a Phase ½ clinical trial investigating a new antibody therapy. The therapy has been developed to target a variant of the common tumor marker HER2 that is treatment-resistant.
That variant form is called p95HER2, and it appears in up to 40% of HER2+ cancers. However, some tumors manage to strip part of the HER2 receptor that most therapies are designed to recognize.
A New Antibody
AP402 is a clinical-stage bispecific antibody that has two separate binding sites. This allows it to bind to two different antigens simultaneously.
The antibody has been developed to:
- target p95HER2
- enlist T-cells to attack tumors
- address HER2+ cancers that are treatment-resistant.
Preclinical data will be presented at the annual meeting of the AACR during the latter part of April in support of AP402’s potential.
AP402 targets the treatment-resistant variant of the tumor marker HER2 that does not respond to standard treatments.
AP402 is slated to be the first bispecific clinical stage antibody to address HER2+ treatment-resistant cancers and enlist T-cells to attack tumors.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
breast cancer breast cancer treatment cancer cancer awareness cancer research clinical trial Clinical Trials HER2 positive cancer HER2-positive breast cancer HER2+ breast cancer HER2+ cancer research
Last modified: April 29, 2025
